Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Ranzani

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of Medicinal Chemistry|October 6, 2022
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase ThetaMartin L Stockley, Amanda Ferdinand, Giovanni Benedetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacyHelen M R Robinson, Vera Grinkevich, Jayesh B Majithiya, et al.
Nature Communications|June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor TypesPatrick G Pilié, Virginia Giuliani, Wei-Lien Wang, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of Medicinal Chemistry|October 6, 2022
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase ThetaMartin L Stockley, Amanda Ferdinand, Giovanni Benedetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacyHelen M R Robinson, Vera Grinkevich, Jayesh B Majithiya, et al.
Nature Communications|June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2024
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor TypesPatrick G Pilié, Virginia Giuliani, Wei-Lien Wang, et al.
Pageof 3